The Tufts Center for the Study of Drug Development and Medidata Solutions Inc analyzed data from 9737 protocols and 130,601 investigative site contracts associated with these protocols to derive updated benchmarks characterizing protocol complexity. The results of the study indicate that protocol design complexity continues to grow rapidly. Nearly all phase I, II, and III complexity measures associated with protocol execution increased significantly (eg, P < .0001) from 2001-2005 to 2011-2015. These measures include the number of unique and total procedures performed per patient over the course of a study, the site work effort to administer protocol procedures, the number of study volunteer visits, and the total number of procedures performed per study volunteer visit. The total cost per planned study volunteer per visit also increased significantly (eg, P < .0001) as did the total cost per study volunteer across all planned study visits. Phase I protocols remain the most complex and the most demanding to execute. Phase III protocols have seen the most substantial growth in protocol complexity. Phase IV protocols saw only modest increases in executional complexity during the 10-year time horizon. The implications of the study findings are discussed.
Introduction
Principal investigators, study coordinators, professionals from pharmaceutical and biotechnology companies, and contract research organizations have all noted increases in the number of study endpoints and objectives, the number of study volunteer eligibility criteria, and the number of procedures administered per protocol. 1, 2 Many factors contribute to this collective experience and will no doubt continue to increase protocol design complexity in the future.
A large and growing proportion of investigational drugs target chronic, difficult-to-treat illnesses, seek more specific patient subpopulations, and require longer and more elaborate methods to measure safety and efficacy endpoints. A growing number of clinical trials collect data to test companion diagnostics and cotherapies, gather economic and outcomes data, collect genetic material and biomarker data, and to feed intellectual curiosity. 1, 3 More ambitious protocols are being designed to collect additional clinical data-particularly safety data-that sponsors anticipate will be required by regulatory agencies and health authorities.
To help interpret study findings and guide development decisions, clinical scientists and statisticians often collect more data than clinically required by the protocol. These insightgenerating variables may not appear in any statistical plan but they may provide clinical validation and explanation for unusual and unexpected results that may be observed during a clinical trial. Clinical scientists may also perform more procedures and collect additional study data with the hope that should the study fail to meet its original objectives, post hoc analyses will reveal useful new insights into the characteristics and treatment of disease, contributing to the discovery of a novel therapy.
Protocol design complexity may also reflect authoring processes and practices and risk avoidance tactics. Medical and protocol-writing professionals may incorporate outdated and unnecessary procedures into new protocols because those procedures are included in legacy authoring templates and policies. Also, clinical teams may collect additional data as a precautionary measure to contribute to the positioning of the investigational therapy post launch.
A substantial and growing body of peer-reviewed literature corroborates real-world protocol design practices. The literature provides ample evidence documenting and quantifying complexity, the strain that it places on professionals administering procedures, the burden that it places on study volunteer participation experience, and the impact that complex designs have on clinical trial performance and cost. [4] [5] [6] Many collaborative research studies conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD) and Medidata Solutions, Inc (Medidata), and published in peer-reviewed journals since 2008 have contributed to this body of knowledge. These studies have quantified ongoing increases in protocol scope, study volunteer eligibility criteria, procedures, and the site work effort to administer them. The evidence presented in these studies has not been imputed or extrapolated: These studies are based on actual protocol design practices, clinical trial performance, and economic data provided directly by major and midsized pharmaceutical and biotechnology companies.
Recent studies have provided updated benchmarks on endpoints and the procedures that support them. During the past decade, the total number of protocol endpoints has nearly doubled. Protocols evaluated across the most recent 10-year time period show only a modest increase in the number of primary and core secondary endpoints but a substantial increase in noncore secondary, tertiary, and exploratory endpoints, 7, 8 reflecting growing demand for supplementary protocol data.
A 2008 Tufts CSDD-Medidata study observed a six-year upward trend in the complexity of protocol designs between 1999 and 2005. 9 The study reported that the number of study volunteer eligibility criteria increased substantially, as did the number and frequency of procedures conducted per protocol. The benchmarked protocol design practices captured in this 2008 study, however, are now more than 10 years old.
This current article provides updated benchmark data characterizing trends in protocol design practice and enables drug development sponsors to compare against their own organizational practices. Using the wealth of new clinical trial data gathered through 2015, this article focuses on protocol design practices by clinical research phase. A subsequent paper will provide benchmarks by therapeutic area.
Methods
We analyzed detailed protocol and investigative site contract data from more than 178 global pharmaceutical and biotechnology companies using Medidata's PICAS database. In all, 9737 protocols were evaluated-76% of the protocols were provided by major companies (eg, the top 25 largest) and 24% by midsized and smaller companies. All protocols included in this analysis received ethical review board approval between 2001 and 2015. Medidata's PICAS database also provided protocol procedure cost data based on 130,601 investigative site contracts. Table 1 presents the distribution of the total sampling of protocols by phase.
A number of protocol design elements were analyzed, including the number of distinct procedures performed per protocol; the total number of procedures performed (ie, sum of distinct procedures multiplied by their frequency) per protocol, the total number of planned study volunteer visits per protocol, the number of procedures performed per planned study volunteer visit; and the total cost per planned study volunteer per visit. These elements, the majority of which characterize the feasibility of protocol execution, are consistent with those variables evaluated in past studies.
Procedures were organized into the following categories: lab tests (including tests, panels, and cultures for vitamin levels, infectious and bacterial agents, and toxins); blood work (including tests and assays examining hematology and coagulation, such as blood counts, bone marrow compositions, and prothrombin/thromboplastin); questionnaires and subjective assessments (including self-administered or physicianadministered questionnaires, rating scales, and assessments for psychological and medical conditions); office consultations and examinations (including full evaluation and procedures for medical and psychological conditions, both new patient and follow-up examinations); radiographs and imaging (including preventative and diagnostic procedures, including ultrasonographs, CT scans, radiographs, and magnetic resonance images of internal organs); and heart activity assessments (including ECGs, EKGs, stress tests, and electro-cardiographic monitoring for both diagnostic and preventative purposes).
The work effort of investigative site personnel to administer protocol procedures was assessed using an approach developed by Tufts CSDD and Medidata in 2008 and integrated into the Medidata PICAS database. This measure is based on Medicare's Relative Value Unit (RVU) methodology, created in 1982 to determine physician reimbursement payment levels based on actual effort and the specific individual involved in executing a given procedure. 10 Medical procedure RVUs were mapped to clinical trial procedures to derive Work Effort Units (WEU) per protocol procedure. 9 In order to gather meaningful insights while reducing any outlier effects observed in any given year, we looked at relatively long time horizons. Trends in protocol design practices were evaluated using 5-year averages to compare three time periods: 2001-2005, 2006-2010, and 2011-2015 . Descriptive statistics (eg, means, medians and coefficients of variation) and inferential statistics were performed. For the latter, t-tests of independent, unpaired samples were conducted using Results Table 2 summarizes the 10-year growth in selected complexity measures by phase. The mean number of planned study volunteer visits for phase I, II, and III protocols increased substantially during this time period. In contrast, phase IV protocols saw a decline in the mean number of visits. The mean number of distinct procedures and the total number of procedures performed per protocol increased dramatically for phases I, II, and III, most notably among phase II and III protocols. Investigative site work effort to administer protocols also increased substantially during the 10-year time period. Average total nominal cost per study volunteer per visit increased substantially for phase I, II, and III protocols. Phase IV protocols generally saw more modest growth across all complexity and cost measures than did phase I, II, and III protocols. Tables 3 to 6 Coefficients of variation (CoVs) around mean values were relatively modest for most phase I complexity variables. The coefficients of variation for many phase I protocol complexity measures tended to be higher in the earlier time period (eg, 2001-2005) than in later periods, suggesting that design practices were more consistent among recently conducted protocols.
The mean number of distinct procedures and the total number of procedures administered to support phase II and III protocols saw high relative growth rates. An average of 24 distinct procedures were performed for each phase II protocol in 2001-2005, compared with 37 in 2011-2015-a significant 54% increase (P < .0001). The average total number of procedures supporting each phase II protocol also increased substantially (67%), from 131 to 219. During this period, the average number of planned study volunteer visits per protocol rose from 13 to 16, representing a smaller (23%) increase. As a result, there are a higher number of procedures performed per planned visit, on average, in the most recent observation period. The average cost for a phase II study volunteer per visit increased 61% (P < . The average number of planned study volunteer visits increased 25%. The average total number of procedures performed per planned study volunteer visit grew the fastest among phase III protocols, largely because of the modest increase in the average number of visits. Similarly, the average cost per study volunteer per visit increased by 34%.
Coefficients of variation around mean phase III protocol complexity values were generally modest, indicating more consistency in design practices.
Phase IV protocols saw modest, nonsignificant growth in nearly all complexity measures, including the mean number of distinct procedures; mean total number of procedures; mean number of planned study volunteer visits; and investigative site work effort. The average total cost per study volunteer per visit, however, increased 23% from 2001-2005 to 2011-2015, significant at the P < .0001 level. Compared with those of phase I, II, and III protocols, coefficients of variation around mean phase IV protocol complexity values were generally higher, suggesting greater disparity in design practices. Table 7 Changes in the mean total cost per planned study volunteer visit by phase are presented in Table 8 . These direct nominal costs increased substantially-most notably for phase I and II protocols-from 2001-2005 to 2011-2015. Mean phase I costs per study volunteer visit grew by 50% from $1259 to $1873, representing a 4.1% compound annual increase. Phase II mean total cost grew from $862 to $1386 per planned study volunteer per visit, a 61% overall increase and a 4.9% compound annual growth rate.
Conclusions
The results of this study indicate clearly that design elements associated with protocol execution continue to grow rapidly. The updated benchmarks provided here assist sponsor companies in assessing their own protocol design practices with industry norms to identify opportunities to improve protocol execution feasibility and cost.
Nearly all variables characterizing the complexity of phase I, II, and III protocol execution increased significantly (P < .0001) between the two observation periods 2001-2005 to 2011-2015. These variables include the mean distinct number of procedures, the mean total number of procedures performed, the mean site work effort to administer protocol procedures, the mean number of study volunteer visits, and the mean total number of procedures performed per study volunteer visit (ie, a simple proxy of the patient's participation burden). The variation around average protocol design practices within each phase is higher than that observed in the earlier time period noted in the Getz et al study, 9 suggesting that pharmaceutical and biotechnology companies are implementing less uniform design decisions.
Phase I protocols remain the most complex and the most demanding to execute. Also consistent with the Getz et al study, 9 phase III protocols-those supporting the largest and most costly studies overall-saw the highest relative growth in most complexity measures, including the mean number of distinct procedures and the mean total number of procedures performed. The mean nominal cost per study volunteer per visit also increased substantially. This overall increase occurred at a time when the cost of conducting many procedures has become less expensive as a result of technological advances and market competition (eg, electrocardiogram assessments, radiographs, and imaging). However, declining costs for individual procedures are unable to counter the full effects of rising protocol complexity. In the aggregate, rising total cost per study volunteer per visit is a function of the total number of procedures performed.
This study found that the distribution of procedure categories per protocol changed modestly across the 10-year comparison period with few exceptions, suggesting that the number of procedures in these categories increased commensurably. The proportion of lab tests and blood work in phase I and IV protocols declined, and the proportion of procedures involving study volunteer questionnaires and self-reported outcomes saw higher relative growth. These procedure categories are disproportionately reducing and increasing, respectively, the overall growth in distinct and total procedures per protocol.
Protocol complexity measures-including the mean number of distinct and total procedures and their 10-year growth ratesby therapeutic area varied widely. Protocols for investigational treatments targeting diseases in oncology and immunology had the highest average number of procedures. Protocols targeting respiratory diseases saw the most rapid 10-year growth rate. At the present time, we are preparing a subsequent paper that comprehensively summarizes benchmark protocol complexity characteristics and growth rates by therapeutic area.
The study findings are compelling given the increased attention that drug development sponsors are placing on improving executional feasibility to address poor clinical trial performance and the failure to engage with patients and health care providers. Several studies demonstrate that more complex protocol designs are associated with longer cycle times, higher numbers of protocol amendments, and lower patient recruitment and retention rates. 9, 11, 12 A number of studies have also shown that the collection of excessive and unnecessary clinical data may compromise data integrity and the data analysis process and may ultimately drive longer study durations and delay submissions to regulatory agencies. [13] [14] [15] Several studies in the literature also show that health professionals are less likely to refer patients to, and patients are less likely to participate in, more complex clinical trials. 16 A growing number of pharmaceutical and biotechnology companies and their contract research organization (CRO) partners are taking steps to optimize protocol designs to improve executional feasibility, ease site and subject participation burden, and gather more meaningful clinical data. These initiatives include the use of protocol review committees, protocol authoring practices connecting procedures to primary and key secondary endpoints, common protocol authoring templates, and soliciting feedback on draft protocol designs from patients and investigative site staff prior to approval and execution.
Tufts CSDD studies have not yet detected any impact from these initiatives. Early reports suggest that these initiatives are beginning to yield reductions in the number of protocol amendments and improvements in investigative site administration burden. 17 Future research will continue to monitor and benchmark protocol design practices and their impact on clinical trial performance, cost, and efficiency.
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